France's Sanofi Halts Work On mRNA COVID-19 Vaccine
NDTV
Sanofi said it would focus instead on another type of jab it is developing with British drug maker GlaxoSmithKline and which is in the final phase of human trials.
French pharmaceutical giant Sanofi said Tuesday it was stopping work on an mRNA vaccine against Covid-19 despite positive test results as it lags behind rivals on producing a coronavirus shot.
The company said it would focus instead on another type of jab it is developing with British drug maker GlaxoSmithKline and which is in the final phase of human trials.
Sanofi's mRNA vaccine -- the ground-breaking technology used by rivals Pfizer/BioNTech and Moderna -- had positive results in phase one and two of clinical trials, the firm said.
But Sanofi said it will not take it into the third and final phase, arguing that it would arrive too late to market with 12 billion Covid doses due to be produced by the end of the year.
